GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as GDC-0449, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase I trial is studying the side effects and best dose of GDC-0449 in
treating patients with locally advanced or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.
Collaborators:
National Cancer Institute (NCI) Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins